Any discrepancies were resolved by discussion. Data Selleck PS-341 Synthesis The results of individual studies (expressed as event rates or adjusted

for confounding factors odds ratios [ORs] or RR), summarized in evidence tables to analyze differences in incontinence in categories by age, race, ethnicity, and risk factors, are available at http://www.ahrq.gov/downloads/pub/evidence/pdf/fuiad/fuiad.pdf. Definitions of Incontinence. We analyzed incontinence using the definitions of signs and symptoms of UI promoted by the ICS, including stress, Inhibitors,research,lifescience,medical urge, and mixed incontinence.1,5,21 Continence was defined as self-reported absence of involuntary urine loss or negative results on stress and pad tests. Frequency of UI was abstracted as daily, weekly, or monthly episodes of urine leakage. Severity of incontinence was defined using the objectively measured urine loss in pad weight tests or self-reported pad use. We defined true Inhibitors,research,lifescience,medical population incidence as newly diagnosed cases of incontinence that developed Inhibitors,research,lifescience,medical annually in the target population. True population incidence estimates were derived from large population-based surveys. However, for clinical interventions we defined incidence as the probability of developing incontinence

under study after active and control interventions during time of follow-up.1,22 We defined reported incontinence as the prevalence of total incontinence or episodes of different types of incontinence when the authors did not access continence status as baseline or did not exclude prevalence Inhibitors,research,lifescience,medical cases from overall estimation. We analyzed continence separately from improvement in incontinence because continence is the most clinically desirable patient outcome and is well defined, whereas improvement can Inhibitors,research,lifescience,medical include substantial differences in definitions and changing perceptions of qualitative and quantitative parameters of improvement. We used such conservative approaches to generate precise estimates of the effectiveness. Clinicians

and patients can make informed decisions on the basis of the treatments that resulted in greater rates of long-term continence in L-NAME HCl well-designed RCTs. We applied the intention-to-treat principle and calculated the number of cases in the active and control groups. Pooling criteria included the same operational definitions of incontinence outcomes and the same risk factors or clinical interventions.23 Homogeneity in clinical interventions was analyzed comparing published information on behavioral, instrumental (devices), pharmacologic, and surgical treatments. Meta-analysis was used to assess the consistency of the association between treatments and incontinence outcomes with random-effects models.24 Consistency in results was tested by comparing the direction and strength of the association.